Second-Generation GLP-1
Dual GIP/GLP-1 Agonist
Best For
Clients who have plateaued on other protocols, comprehensive metabolic support
GIP+GLP-1
Dual incretin pathways studied for metabolic effects
Dual
Two incretin receptors engaged simultaneously
Appetite
Hypothalamic appetite signaling studied
How It Works
This second-generation GLP-1 activates both GIP and GLP-1 receptors simultaneously — two of the three major incretin pathways. This dual mechanism produces superior appetite reduction, improved insulin sensitivity, and enhanced fat oxidation compared to single-pathway agents. The GIP activation appears to independently improve fat metabolism and may contribute to lean mass preservation during weight loss.
Key Research Areas
Appetite Control
Studied for effects on hunger signaling via hypothalamic pathways
Metabolic Research
Examined in clinical trials for effects on body weight and metabolism
Blood Sugar
Improves insulin sensitivity and fasting glucose
Cardiovascular
Emerging data shows reduction in heart attacks and stroke risk
Research Highlights
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Featured Research
Formulation Notes
Common concentrations referenced in published clinical studies:
[TR20]20mg[TR40]40mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Third-Generation GLP-1
Triple GLP-1/GIP/Glucagon Agonist
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Reference Codes
[RT20]20mg[RT30]30mgFirst-Generation GLP-1
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgAmylin + GLP-1 Combination
Amylin + GLP-1 Dual Agonist
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Reference Codes
[CS10]10mg (Amylin 5mg + GLP-1 5mg)Evidence reviewed: March 2026